For example, the STEP 1 trial of once-weekly semaglutide (2.4 mg) in people without diabetes achieved a ~15% average body weight reduction over 68 weeks (source), with a mean baseline BMI of ~38 (source)
Because of its triple-action mechanism, it appears to have a broader metabolic impact compared with traditional GLP-1 agonists like Wegovy and Mounjaro
Pharmaceutical GLP-1 agonistssuch as semaglutidehave become popular, but they are synthetic, require prescriptions, and may carry side effects with long-term use
Better blood pressure management 41% of patients in the 8 mg groups and 30% in the 12 mg group were able to stop taking at least one antihypertensive medication after 48 weeks on retatrutide
The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)
Holding the bottle in your hand for 1-2 minutes before dosing takes the edge off the cold without compromising stability
